| First Author | Hameed MQ | Year | 2023 |
| Journal | Ann Clin Transl Neurol | Volume | 10 |
| Issue | 9 | Pages | 1695-1699 |
| PubMed ID | 37452008 | Mgi Jnum | J:350967 |
| Mgi Id | MGI:7663240 | Doi | 10.1002/acn3.51851 |
| Citation | Hameed MQ, et al. (2023) Depressed glutamate transporter 1 expression in a mouse model of Dravet syndrome. Ann Clin Transl Neurol 10(9):1695-1699 |
| abstractText | Dravet syndrome (DS) is a monogenic, often refractory, epilepsy resultant from SCN1A haploinsufficiency in humans. A novel therapeutic target in DS that can be engaged in isolation or as adjunctive therapy is highly desirable. Here, we demonstrate reduced expression of the rodent glutamate transporter type 1 (GLT-1) in a DS mouse model, and in wild type mouse strains where Scn1a haploinsufficiency is most likely to cause epilepsy, indicating that GLT-1 depression may play a role in DS seizures. As GLT-1 can be upregulated by common and safe FDA-approved medications, this strategy may be an attractive, viable, and novel avenue for DS treatment. |